Zuo Zan, Fan Hong, Tang Xiao-Dan, Chen Yan-Min, Xun Lin-Ting, Li Yan, Song Zheng-Ji, Zhai Hui-Qiong
College of Environmental Science and Engineering, Kunming University of Science and Technology, Kunming, Yunnan 650500, P.R. China.
Department of Gastroenterology, Affiliated Hospital of Kunming University of Science and Technology, The First People's Hospital of Yunnan, Kunming, Yunnan 650532, P.R. China.
Exp Ther Med. 2017 Nov;14(5):4887-4895. doi: 10.3892/etm.2017.5141. Epub 2017 Sep 19.
Minimal hepatic encephalopathy (MHE) is caused by dysbiosis of gut microbiota, particularly the ammonia-producing bacteria. Given the efficacy of certain treatments on MHE and the connection between alcoholism and MHE, a thorough understanding of how these strategies affect the gut microbiota in patients (alcoholic or non-alcoholic) will facilitate the assessment of their efficacy in the reshaping of gut microbiota. In the present study, a metagenomics approach was adopted to reveal alterations in gut microbiota of 14 MHE patients following treatment with rifaximin alone or rifaximin plus probiotics. Patients were grouped into the alcoholic and non-alcoholic groups to examine differences in terms of their response to treatment. Treatment reduced the overall microbiota diversity and decreased the abundance of certain ammonia-producing bacteria, such as , with the treatment of rifaximin plus probiotics presenting a more apparent effect. Non-alcoholic MHE patients responded better to the treatment, as they presented greater reduction in microbiota diversity and a more consistent decline in certain ammonia-producing bacteria genera (such as and ) belonging to the Firmicutes phylum. In conclusion, treatment with rifaximin alone and rifaximin plus probiotics exhibited a different effect in different MHE patients, decreasing the overall gut microbiota diversity to various extents and reshaping microbiota in different ways. Furthermore, non-alcoholic MHE patients responded better to treatment in microbiota alterations.
轻微肝性脑病(MHE)由肠道微生物群失调引起,尤其是产氨细菌。鉴于某些治疗方法对MHE的疗效以及酗酒与MHE之间的联系,深入了解这些策略如何影响患者(酗酒或非酗酒)的肠道微生物群将有助于评估其在重塑肠道微生物群方面的疗效。在本研究中,采用宏基因组学方法揭示14例MHE患者单独使用利福昔明或利福昔明加益生菌治疗后肠道微生物群的变化。患者分为酗酒组和非酗酒组,以检查他们对治疗反应的差异。治疗降低了整体微生物群多样性,并降低了某些产氨细菌的丰度,如 ,利福昔明加益生菌治疗效果更明显。非酒精性MHE患者对治疗反应更好,因为他们的微生物群多样性降低幅度更大,属于厚壁菌门的某些产氨细菌属(如 和 )的下降更一致。总之,单独使用利福昔明和利福昔明加益生菌治疗在不同的MHE患者中表现出不同的效果,不同程度地降低了整体肠道微生物群多样性,并以不同方式重塑微生物群。此外,非酒精性MHE患者对治疗引起的微生物群改变反应更好。